Pre-made Teclistamab biosimilar ( Bispecific mAb, anti-TNFRSF17;CD3E therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-557
Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Teclistamab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Teclistamab is an off-the-shelf, T-Cell redirecting, bispecific antibody targeting both BCMA and CD3 receptors. BCMA is expressed at high levels on multiple myeloma cells. 4,5,6,7,8. Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce killing of tumor cells.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Teclistamab biosimilar,Bispecific mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Companies||Genmab;Janssen Research & Development|
|Conditions Active||Multiple myeloma|